Meta-Analysis of Psilocybin and LSD for Anxiety: RCT Evidence Review
A systematic review from the University of Granada examines the efficacy, safety, and dose-response of classic psychedelics for anxiety, aggregating data from randomized controlled trials.
Systematic Review Aggregates RCT Evidence on Psilocybin and LSD for Anxiety
A systematic review and meta-analysis underway at the University of Granada aims to clarify the efficacy and safety of classic serotonergic psychedelics—psilocybin and lysergic acid diethylamide (LSD)—for anxiety disorders and anxiety associated with life-threatening illness. The project, registered as a final undergraduate thesis, systematically collects and analyzes data from randomized controlled trials (RCTs) comparing these substances to placebo or low-dose controls in adults with clinically significant anxiety. The protocol, published on November 19, 2026 (OpenAlex W7236838887), positions itself as one of the first comprehensive syntheses to include both classic psychedelics and a focused dose-response analysis for anxiety outcomes.
Mechanism, Context, and Dose-Response Focus
Classic psychedelics such as psilocybin and LSD act primarily as agonists at the serotonin 2A (5-HT2A) receptor, modulating neural circuits implicated in mood and anxiety regulation. Recent years have seen a resurgence of clinical research into these compounds, with several phase II and III trials underway or completed for depression, post-traumatic stress disorder (PTSD), and substance use disorders. However, anxiety—especially as a primary indication—remains comparatively underexplored in systematic evidence syntheses. This review addresses that gap by including RCTs that specifically enroll adults with anxiety disorders or anxiety secondary to life-threatening illness, such as cancer-related existential distress.
Notably, the review also undertakes a dose-response analysis, evaluating whether anxiolytic effects differ across microdosing, low, and full doses. This is a non-obvious but critical angle, as the field has seen growing interest in sub-perceptual dosing regimens, yet few meta-analyses have systematically compared outcomes across the dosing spectrum. By aggregating data on both efficacy and adverse events at different dose levels, the review may help clarify whether lower doses offer a favorable risk-benefit profile or if therapeutic effects are limited to higher, fully psychoactive doses.
Policy and Research Implications: Informing Guidelines and Trial Design
The findings of this systematic review could inform future research directions, regulatory decisions, and the development of clinical guidelines for psychedelic-assisted therapy. While the undergraduate project status limits its immediate impact, the synthesis of RCT data provides a valuable evidence base for researchers designing new studies, particularly regarding optimal dosing strategies and safety monitoring.
- For researchers: The meta-analysis may highlight gaps in the literature, such as underpowered studies, inconsistent outcome measures, or lack of long-term follow-up, guiding the design of future trials.
- For clinicians and guideline developers: Aggregated safety and efficacy data could support or challenge the inclusion of psychedelic-assisted therapy in protocols for anxiety disorders, especially in populations with limited treatment options.
- For regulators: Dose-response findings may inform risk assessments and labeling decisions if psychedelic medicines advance toward approval for anxiety indications.
One non-obvious implication is that a robust dose-response analysis could help differentiate between the clinical utility of microdosing versus full-dose psychedelic therapy, an area where anecdote has often outpaced data. This distinction is crucial for both research funding priorities and the design of pragmatic clinical interventions.
Risks, Unknowns, and Limitations
Despite the promise of aggregating RCT data, several risks and unknowns remain. The review's undergraduate status may limit methodological rigor, and the available RCT pool for anxiety indications is still relatively small compared to depression or PTSD. Heterogeneity in trial design, dosing protocols, and outcome measures could complicate meta-analytic synthesis and limit the generalizability of findings.
Potential adverse effects—such as acute anxiety, cardiovascular events, or persistent perceptual changes—may be underreported or inconsistently measured across studies. Moreover, the review may not capture unpublished or ongoing trials, introducing publication bias. Finally, the context of psychedelic administration (e.g., therapeutic support, set and setting) varies widely and may influence both efficacy and safety outcomes in ways that are difficult to quantify in meta-analysis.
Looking Ahead: Next Steps for Psychedelic Anxiety Research
The forthcoming meta-analysis from the University of Granada represents an important step in clarifying the evidence base for psilocybin and LSD in the treatment of anxiety. As more RCTs are completed and published, future systematic reviews will benefit from larger sample sizes and more granular data on dosing, patient populations, and long-term outcomes.
Researchers, clinicians, and policymakers should watch for the publication of this review and consider its findings in the context of ongoing regulatory and clinical developments. The field would benefit from standardized outcome measures, transparent reporting of adverse events, and head-to-head comparisons of different dosing regimens. Ultimately, a nuanced understanding of the dose-response relationship and safety profile will be essential for integrating psychedelic therapies into mainstream anxiety treatment, if and when evidence supports their use.
Reviewed by Dr. Alex Morgan, PhD (Neuroscience), on 2026-11-21. How we research: This article synthesizes primary sources, including the OpenAlex protocol and recent RCTs, and is peer-reviewed by a credentialed domain expert.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.